Evidence map›Paper›PMID 41857302›Full record

ReviewThe AAPS journal2026

Physiologically Based Pharmacokinetic (PBPK) Modeling of Oral Drug Absorption for Integrating Nonclinical Data into Human Pharmacokinetic Predictions.

Xiaomin Liang, Grace Fraczkiewicz, Krutika Meena Harish Jain, Bo Wan, Kazuya Ishida, Yurong Lai

Abstract readReview
PubMed Publisher
In one paragraph

Review in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xiaomin LiangDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr, Foster City, California, 94404, USA. Xiaomin.Liang@Gilead.com.ORCID 0000-0002-8167-4634
Grace FraczkiewiczSimulations Plus, Inc, Research Triangle Park, North Carolina, 27709, USA.ORCID 0009-0002-7061-4799
Krutika Meena Harish JainAnalytical Development, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California, 94404, USA.ORCID 0000-0002-6195-4372
Bo WanAnalytical Development, Gilead Sciences, Inc., 333 Lakeside Dr., Foster City, California, 94404, USA.ORCID 0009-0004-6108-1315
Kazuya IshidaDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr, Foster City, California, 94404, USA.ORCID 0000-0001-7960-9932
Yurong LaiDrug Metabolism, Gilead Sciences, Inc., 333 Lakeside Dr, Foster City, California, 94404, USA.ORCID 0000-0001-9505-333X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Accurate prediction of oral drug absorption is essential for anticipating variability in bioavailability and guiding clinical development. Physiological factors, such as gastric pH, gastric emptying, and intestinal transit time, influenced by food intake and acid-reducing agents (ARAs), play critical roles in the dissolution and absorption of drugs with pH-dependent solubility. Intestinal transporters and metabolizing enzymes also affect systemic exposure by regulating drug absorption, metabolism, and excretion in the intestine. Species differences in gastrointestinal physiology, including pH profiles, transporter expression, and motility patterns, present challenges when translating nonclinical data to humans. Physiologically based pharmacokinetic (PBPK) modeling offers a mechanistic framework to address these variations by integrating drug- and species-specific parameters. By calibrating in vitro and in vivo data, PBPK models can simulate human gastrointestinal conditions and more accurately predict oral absorption dynamics, enhancing translational relevance. These models facilitate early evaluation of food and ARA impacts, transporter-related absorption variabilities, and drug-drug interactions (DDIs), supporting the rational development of formulation and dose selection. Verifying model performance in nonclinical species, commonly in dogs, can further enhance confidence in human predictions. This review highlights drug- and species-specific factors and illustrates how PBPK modeling can address uncertainties regarding drug absorption in humans using nonclinical in vitro and in vivo data. Despite challenges such as parameter uncertainty and interspecies differences, PBPK modeling remains a valuable tool for estimating drug exposure and informing biopharmaceutical and clinical pharmacology strategies.

Indexed as

Intestinal AbsorptionModels, BiologicalPharmacokineticsAdministration, OralAnimalsBiological AvailabilityDrug InteractionsFood-Drug InteractionsHumansPharmaceutical PreparationsSpecies SpecificityPharmaceutical Preparationsfood effectintestinal transportersoral drug absorptionPBPK modelingP-glycoprotein

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.